

# Supplementary information

## Highly effective identification of drug targets at proteome level

### by pH-dependent protein precipitation

Xiaolei Zhang,<sup>a</sup> Keyun Wang,<sup>a</sup> Sijin Wu,<sup>a</sup> Chengfei Ruan,<sup>a</sup> Kejia Li,<sup>a</sup> Yan Wang,<sup>a</sup> He Zhu,<sup>a</sup>

**Xiaoyan Liu,<sup>a</sup>** Zhen Liu,<sup>a</sup> Guohui Li,<sup>\*a</sup> Lianghai Hu<sup>\*b</sup> and Mingliang Ye<sup>\*a</sup>

<sup>a</sup> CAS Key Laboratory of Separation Sciences for Analytical Chemistry, National Chromatographic R & A Center, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China

<sup>b</sup> Center for Supramolecular Chemical Biology, State Key Laboratory of Supramolecular Structure and Materials, School of Life Sciences, Jilin University, Changchun 130012, China

\*Corresponding authors.

E-mail addresses: mingliang@dicp.ac.cn (M. Ye), lianghaiu@jlu.edu.cn (L. Hu), ghli@dicp.ac.cn (G. Li)

## Supplementary tables and figures

Table S1 pH corresponding to the molar concentration of different acidic agents.

Table S2 Subunits of 19 S regulatory particle were stabilized by AMP-PNP.

Fig. S1 Acidic agents-induced denaturation of the K562 proteome.

Fig. S2 Identification of target protein of small molecules AMP-PNP and SNS-032.

Fig. S3 Examples of stability shift curves for non-protein kinase such as ADK, PMPCA, PDCD10 and uncharacterized protein FLJ45252 in the presence or absence of staurosporine.

Fig. S4 Number of total protein quantified by TPP-Savitski, pHDPP, in-house TPP and SIP approaches.

Fig. S5 Overlapped protein in the filtering datasets of pHDPP with in-house TPP and SIP.

Fig. S6 Examples of stability shift curves where protein kinases were stabilized by staurosporine in pHDPP but not stabilized in in-house TPP and SIP approaches.

Fig. S7 Examples of stability shift curves for HMGB2, PSMB3, PSMB4 and PSMB7 related to apoptosis pathway in DHA experiment.

Table S1 pH values corresponding to the molar concentration of different acidic agents

	1mM	3mM	6mM	9mM	12mM	15mM	17mM	20mM
<b>Vc</b>	7.01	6.66	6.02	5.03	4.23	3.90	3.77	3.62
<b>HCl</b>	7.01	6.61	5.91	4.52	3.37	-	-	-
<b>FA</b>	7.01	6.60	5.80	4.07	3.50	-	-	-
	1mM	2mM	3mM	4mM	5mM	6mM		
<b>CA</b>	6.70	6.20	5.68	4.93	4.40	3.78		

The different concentrations of Vc, CA, HCl and FA were added in 10 mM PBS buffer to simulate the environment of the protein solution in Fig. S1.

Table S2 Subunits of 19 S regulatory particle were stabilized by AMP-PNP

IDs	Gene	Protein name	Ratio H/L-1	Log2-1	Ratio H/L-2	Log2-2
P62333	PRS10	26S proteasome regulatory subunit 10B	0.19	2.43	0.11	3.15
P62191	PRS4	26S proteasome regulatory subunit 4	0.14	2.88	0.14	2.79
P17980	PRS6A	26S proteasome regulatory subunit 6A	0.17	2.57	0.21	2.23
P43686	PRS6B	26S proteasome regulatory subunit 6B	0.21	2.25	0.14	2.83
P35998	PRS7	26S proteasome regulatory subunit 7	0.10	3.27	0.15	2.72
P62195	PRS8	26S proteasome regulatory subunit 8	0.13	2.93	0.15	2.70
O00231	PSD11	26S proteasome non-ATPase regulatory subunit 11	0.17	2.52	0.17	2.58
O00232	PSD12	26S proteasome non-ATPase regulatory subunit 12	0.24	2.05	0.21	2.27
Q9UNM6	PSD13	26S proteasome non-ATPase regulatory subunit 13	0.16	2.68	0.17	2.55
O00487	PSDE	26S proteasome non-ATPase regulatory subunit 14	0.17	2.57	0.17	2.52
Q99460	PSMD1	26S proteasome non-ATPase regulatory subunit 1	0.14	2.87	0.18	2.46
Q13200	PSMD2	26S proteasome non-ATPase regulatory subunit 2	0.11	3.15	0.13	2.90
O43242	PSMD3	26S proteasome non-ATPase regulatory subunit 3	0.21	2.22	0.22	2.17
P55036	PSMD4	26S proteasome non-ATPase regulatory subunit 4	0.26	1.94	0.21	2.27
Q15008	PSMD6	26S proteasome non-ATPase regulatory subunit 6	0.30	1.74	0.28	1.82
P51665	PSMD7	26S proteasome non-ATPase regulatory subunit 7	0.29	1.77	0.28	1.82
P48556	PSMD8	26S proteasome non-ATPase regulatory subunit 8	0.20	2.35	0.18	2.49




Fig. S1 Acidic agents-induced denaturation of the K562 proteome. K562 lysates were treated with 14 increasing concentrations of different acidic agents. The proteins in soluble fractions were separated by SDS-PAGE and visualized with Coomassie staining.





Fig. S2 Identification of target protein of small molecules AMP-PNP and SNS-032. (A) Identification of stabilized proteins in 3mM, 6mM and 9mM Vc-treated samples by AMP-PNP based on quantitative proteomics. (B) Western blotting confirmed the known target CDK9 was stabilized by SNS-032 in 293T cell lysate.




Fig. S3 Examples of stability shift curves for non-protein kinase such as ADK, PMPCA, PDCD10 and uncharacterized protein FLJ45252 in the presence or absence of staurosporine.




Fig. S4 Number of total protein quantified by TPP-Savitski <sup>[1]</sup>, pHDPP, in-house TPP and SIP approaches.

[1] Savitski, M.M., et al., *Tracking cancer drugs in living cells by thermal profiling of the proteome*. Science, 2014. **346**(6205): 1255784.






Fig. S5 Overlapped protein in the filtering datasets of pHDPP with in-house TPP and SIP.




Fig. S6 Examples of stability shift curves where protein kinases were stabilized by staurosporine in pHPPP but not stabilized in in-house TPP and SIP approaches.




Fig. S7 Examples of stability shift curves for HMGB2, PSMB3, PSMB4 and PSMB7 related to apoptosis pathway in DHA experiment.